First renin inhibitor, aliskiren, for the treatment of hypertension
- 86 Downloads
Aim of the review To systematically analyze the efficacy and safety of aliskiren for the treatment of hypertension in comparison to placebo, other monotherapy, and various combination therapies. Method A PubMed database (1966-June 2008) search was conducted with aliskiren as a search term with limits of humans, written in English, and in title only. Phase III pivotal clinical studies retrieved by PubMed database and resources such as printed labeling, approval letter, pharmacology reviews, and medical reviews posted in Drug@FDA website were evaluated with regard to study design and outcomes of efficacy and safety. Results Six Phase III pivotal clinical studies compared various doses of aliskiren to placebo and some studies compared aliskiren to treatment with other monotherapies or combinations. Aliskiren in doses of 300 mg showed a statistically significant reduction in both systolic and diastolic blood pressure versus placebo. Comparison to other antihypertensive treatments suggest that aliskiren doses of 150 and 300 mg may induce blood pressure changes similar to those seen with moderate doses of hydrochlorothiazide or angiotensin receptor blockers. Aliskiren in combination with angiotensin receptor blockers or hydrochlorothiazide showed additional blood pressure reduction only when higher doses of aliskiren were used. Aliskiren appears to be well tolerated, with diarrhea being the only statistically significant adverse event. Conclusion Aliskiren is a novel antihypertensive that exerts its effects through the direct inhibition of renin. Although the drug is well tolerated, its modest effects on blood pressure and the present lack of evidence of impact on objective cardiovascular outcomes appear to limit its utility in the general treatment of hypertension at this time.
Key wordsAdverse events Aliskiren Blood pressure Efficacy Hypertension Renin inhibitor
The authors wish to acknowledge the support of the Yeungnam University, South Korea.
This research was supported by the Yeungnam University research grant in 2007.
Conflicts of Interest
The authors have no conflicts of interest to declare.
- 1.Approval Letter. http://www.fda.gov/cder/foi/nda/2007/021985s000_APPROV.pdf Accessed on 23 June 2008.
- 2.Pharmacology Review Part 2. http://www.fda.gov/cder/foi/nda/2007/021985s000_PharmR_P2.pdf Accessed on 23 June 2008.
- 3.Pharmacology Review Part 3. http://www.fda.gov/cder/foi/nda/2007/021985s000_PharmR_P3.pdf Accessed on 23 June 2008.
- 6.Azizi M, Ménard J, Bissery A, Guyenne TT, Bura-Rivière A, Vaidyanathan S, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126–33. doi: 10.1097/01.ASN.0000146686.35541.29.PubMedCrossRefGoogle Scholar
- 9.Kalus J. Aliskiren: a novel oral renin inhibitor for the treatment of hypertension. Formulary. 2006;41:631–8.Google Scholar
- 11.Villamil A, Chrysant SG, Calhoun D, Schober B, Hsu H, Matrisciano-Dimichino L, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25:217–26. doi: 10.1097/HJH.0b013e3280103a6b.PubMedCrossRefGoogle Scholar
- 19.Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012–8. doi: 10.1161/01.CIR.0000156466.02908.ED.PubMedCrossRefGoogle Scholar
- 22.Label Information of Tekturna. http://www.fda.gov/cder/foi/nda/2007/021985s000_PRNTLBL.pdf Accessed on 23 June 2008.
- 23.Medical Review Part 1. http://www.fda.gov/cder/foi/nda/2007/021985s000_MedR_P1.pdf Accessed on 23 June 2008.
- 24.Medical Review Part 2. http://www.fda.gov/cder/foi/nda/2007/021985s000_MedR_P2.pdf Accessed on 23 June 2008.
- 25.Medical Review Part 3. http://www.fda.gov/cder/foi/nda/2007/021985s000_MedR_P3.pdf Accessed on 23 June 2008.
- 26.Pharmacology Review Part 4. http://www.fda.gov/cder/foi/nda/2007/021985s000_PharmR_P4.pdf Accessed on 23 June 2008.
- 27.World Health Organization. Chapter 4: Quantifying selected major risks to health. In: The World Health Report 2002 (reducing risks, promoting healthy life). Geneva, Switzerland, 2002. p. 57.Google Scholar
- 29.Efstratopoulos AD, Voyaki SM, Baltas AA, Vratsistas FA, Kirlas DE, Kontoyannis JT, et al. Prevalence, awareness, treatment and control of hypertension in Hellas, Greece: the hypertension study in general practice in Hellas (HYPERTENSHELL) national study. Am J Hypertens. 2006;19:53–60. doi: 10.1016/j.amjhyper.2005.07.011.PubMedCrossRefGoogle Scholar